TRPA1 and osteoarthritis: Ms 9a-1 significantly potentiates agonist-induced currents of TRPA1 in vitro [17], but intravenous or subcutaneous injection of Ms 9a-1 (0.1–0.3 mg/kg) reduces pain, inflammation, and hyperalgesia in different models of pain [17,18], including MIA-induced osteoarthritis [19].